China NDA approves Opdivo (nivolumab injection) for previously treated NSCLC
Bristol-Myers Squibb announced the China National Drug Administration has approved Opdivo (nivolumab injection) for treatment of locally advanced or metastatic non-small cell lung cancer after prior platinum-based chemotherapy in adult patients without EGFR or ALK genomic tumor aberrations. June 15, 2018